Clinical Trial Update: Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine [Phase 3]

View source ↗

Summary

Phase 3 inter-lot consistency study update for an adsorbed cell-free diphtheria-tetanus-pertussis vaccine developed by CanSino Biologics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• DTP vaccine (adsorbed, cell-free, three-component) (diphtheria-tetanus-pertussis vaccine (adsorbed, cell-free, three-component))

Snippet

Sponsor: CanSino Biologics Inc. | Conditions: Diphtheria, Tetanus and Acellular Pertussis | Phase 3 | Status: ACTIVE_NOT_RECRUITING